Van ECK Associates Corp Invests $37,000 in Abcam plc (NASDAQ:ABCM)

Van ECK Associates Corp bought a new position in Abcam plc (NASDAQ:ABCM – Get Rating) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,501 shares of the company’s stock, valued at approximately $37,000.

Several other large investors have also added to or reduced their stakes in ABCM. Truist Financial Corp boosted its holdings in Abcam by 42.3% in the third quarter. Truist Financial Corp now owns 37,827 shares of the company’s stock valued at $567,000 after acquiring an additional 11,243 shares in the last quarter. Brown Advisory Inc. boosted its holdings in Abcam by 8.6% in the second quarter. Brown Advisory Inc. now owns 3,168,283 shares of the company’s stock valued at $45,813,000 after acquiring an additional 252,025 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Abcam by 26.3% in the second quarter. Price T Rowe Associates Inc. MD now owns 1,553,124 shares of the company’s stock valued at $22,458,000 after acquiring an additional 323,670 shares in the last quarter. DF Dent & Co. Inc. boosted its holdings in Abcam by 9.6% in the second quarter. DF Dent & Co. Inc. now owns 816,673 shares of the company’s stock valued at $11,809,000 after acquiring an additional 71,691 shares in the last quarter. Finally, Citadel Advisors LLC boosted its holdings in Abcam by 20.4% in the second quarter. Citadel Advisors LLC now owns 130,697 shares of the company’s stock valued at $1,890,000 after acquiring an additional 22,182 shares in the last quarter. Institutional investors own 13.91% of the company’s stock.

Abcam Price Performance

Shares of Abcam stock opened at $16.36 on Friday. The business has a fifty day simple moving average of $15.98 and a two-hundred day simple moving average of $15.37. Abcam plc has a 12 month low of $12.54 and a 12 month high of $19.39.

Wall Street Analyst Weigh In

Separately, Deutsche Bank Aktiengesellschaft began coverage on shares of Abcam in a report on Tuesday, December 13th. They issued a “hold” rating on the stock.

Abcam Profile

(Get Rating)

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.